Journal Maturitas Publishes Position Statement: “Non-hormonal management of menopausal vasomotor symptoms”
Elsevier journal Maturitas, today announced the publication of a position statement by the European Menopause and Andropause Society (EMAS) covering non-hormonal management of menopausal vasomotor symptoms.
Hot flashes are a common menopausal symptom. They tend to intensify during the perimenopause and usually subside within 5 years after the final menstrual period. However in some women frequent hot flashes are a long term problem and may last for more than 7 years. While estrogen-based menopausal hormone therapy is the most effective treatment it is not indicated for all women, such as those with a personal history of breast cancer. The position statement provides a practical guide to non-hormonal management.
It covers lifestyle modifications, diet and food supplements, non-hormonal medications and use of behavioral and alternative medicine therapies. The key conclusions are that there is insufficient or conflicting evidence to suggest that exercise, supplements or a diet rich in phytoestrogens are effective for hot flashes. Selective serotonin-reuptake inhibitors (SSRIs), serotonin norepinephrine-reuptake inhibitors (SNRIs) and gabapentin could be proposed as alternatives to estrogen-based therapies. Behavioral therapies and alternative medicine interventions have been tried, but the available evidence is still limited.
Thus women who cannot take estrogens should be able to discuss non-hormonal options with their health professional.
These and other recommendations presented in EMAS’ position statement are published in the article: “EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms” (http://dx.doi.org/10.1016/j.maturitas.2015.04.009) in Maturitas published by Elsevier.
Notes for editors
Copies of this paper are available to credentialed journalists upon request; please contact Elsevier's Newsroom at firstname.lastname@example.org or +31 20 4853564.
About European Menopause and Andropause Society
EMAS promotes the study of midlife health through its journal, congresses, schools and website and encourages the exchange of research and professional experience between members. Using a range of activities and through its affiliates, EMAS aims to guarantee and provide the same standard of education and information throughout Europe on midlife health in both genders. Recognizing the issues arising from increased longevity the society also provides articles, patient information, web resources, and referrals for healthcare providers in the field and keeps its members up-to-date. For more information go to: http://www.emas-online.org
Maturitas is an international multidisciplinary peer reviewed scientific journal of midlife health and beyond, publishing original research, reviews, consensus statements and guidelines. The scope encompasses all aspects of postreproductive health in both genders ranging from basic science to health and social care. http://www.maturitas.org/
Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
+31 20 485 3323